Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gelclair is a concentrated oral gel classified as a medical device used for the management of oral mucositis and other painful oral lesions, particularly those induced by chemotherapy or radiotherapy. It is composed of polyvinylpyrrolidone (PVP), sodium hyaluronate (hyaluronic acid), and glycyrrhetinic acid. The gel functions by adhering to the oral mucosa and forming a protective physical barrier that coats exposed nerve endings, hydrates tissues, and provides symptomatic relief from pain. It does not contain traditional pharmacologically active ingredients and acts through mechanical protection rather than biological receptor interaction, although glycyrrhetinic acid is noted for providing anti-inflammatory effects as a cyclooxygenase inhibitor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gelclair.